Previous events

Immunotherapy insights: Biomarker testing and multi-disease treatment options

28th September 2023, 12:00pm CET

In the first event of this exciting series, key opinion leaders from the precision oncology field shared insights on the state of the art both in terms of biomarker testing and clinical utility of the use of immunotherapy as a multi-disease treatment option. Dr. Luiz Paz-Ares, Hospital Universitario 12 de Octubre, and Dr. Phillipe Taniere, University Hospitals Birmingham, explored across different oncological diseases, the importance of biomarkers such as PD-L1, MMR/MSI, and TMB for immunotherapy response and what are mandatory patient criteria for biomarker testing.

Liquid biopsy in oncohematology: Ready for clinic?

8th November 2023, 13:00 CET.

Event 2 in the series included an illuminating webinar featuring two distinguished experts in the field of oncohematology as they delve into the cutting-edge realm of liquid biopsies, their pivotal role in the detection of minimal residual disease (MRD) and investigate their role in the diagnostics of aggressive B cell lymphoma and multiple myeloma. Guest speakers Dr. Sven Borchmann from the University of Cologne, and Prof. Mattia D'Agostino from the University of Turin will guide participants through liquid biopsy as applied in B cell lymphoma, the profound implications of MRD, and techniques in the context of multiple myeloma and precision medicine. Attendees can participate in interactive sessions and engage in real-time Q&A sessions with the expert speakers, providing a chance to ask questions and gain a deeper insight and understanding of these increasingly relevant topics.

CE-IVDR: where are we now in molecular testing?

12th December 2023, 15:00 CET.

The implementation of the new CE-In Vitro Diagnostics Regulation (IVDR) involves challenges faced by labs that are working within the diagnostic environment. The aim of this event is to get an overview of how IVDR implementation is progressing in different countries, and which are the most relevant challenges from a molecular pathology point of view. Five guest speakers from The Netherlands, France, Spain, Italy, and the UK with experience in the field will share their point of view and discuss the current situation and future perspectives.

The challenges of the pre-analytical phase.

22nd January 2024, 15:00 CET.

Good laboratory practice in the pre-analytical phases of testing is becoming increasingly important regardless of the challenges it presents, and the success of each test depends greatly on this being carried out correctly. The challenge of the pre-analytical phase includes patient identification, collection, handling, and sorting of the sample.

‘The challenges of the pre-analytical phase’ Diaceutics event will include a presentation of how this delicate laboratory phase was, how it is, and how it will be managed. A round-table with three international expert speakers will then be held and moderated, finishing with a Q&A for participants.

Benefits and Limitations of Large Gene Panels for Patient Care

28th February 2024, 13:00 CET

Clinical laboratories around the world are adopting next-generation sequencing (NGS) to detect cancer genomic variations with the aim of enhancing patient outcomes. However, the various sizes of NGS panels come with distinct advantages and limitations for tumour molecular profiling, and their suitability for clinical use varies. In this webinar, our goal is to examine the pros and cons of Amplicon- vs. Hybrid-capture sequencing, and to investigate how panels of different sizes address crucial aspects of clinical testing. Additionally, we aim to emphasize the challenges and the significance of sample quality, panel interpretation, and best laboratory practices by showcasing real case examples. Lastly, we welcome all participants to engage in an open discussion regarding the current status of large panel reimbursement in their respective countries, and, of course, to pose questions to the presenter.

The Future of Digital Pathology and NGS for Cytopathology Samples

26th March 2024, 16:00 CET

The development of new targeted therapies in oncology requiring therapeutic decision forces pathologists to use more innovative techniques such as NGS and digital pathology to obtain increasingly complex information. But what about the future of digital pathology and NGS for cytopathology samples? These types of samples have the advantage of being minimally invasive, producing few or no side effects in the patient. The result of their analysis can be decisive in knowing whether a lesion requires further investigation, and possibly medical or surgical treatment.
During this sixth event “Precision medicine in oncology” series, we will have two guest speakers Prof. Catarina Eloy and Prof. Jean-Christophe Sabourin, who share their vision of the future of these two innovated methods for cytopathology samples.

Unravelling germline variants in hematology-oncology patients: Management in the era of WGS and NGS

17th April 2024, 15:00 CET

Join us for a comprehensive exploration of germline variants in hematology-oncology patients, navigating the complexities of management in the age of whole genome and next-generation sequencing. Our agenda covers the fundamentals of germline vs somatic variants, insights from UK Germline Workshops, laboratory management strategies, real-life case studies, and a Q&A session. Don't miss this opportunity to unravel the challenges and implications in hematology-oncology settings.